- Home
- Companies
- north america
- cancer genomic screening
Show results for
Refine by
Cancer Genomic Screening Suppliers In North America
37 companies found
based inWest Berlin, NEW JERSEY (USA)
Meda Biotech, LLC was founded in 2003 on the strength of a conviction that a new concept, HYBRID-NANOENGINEERINGTM, could solve insolubility problems and have real therapeutic value for patients. That belief gave birth to a process of continual ...
based inSan Antonio, TEXAS (USA)
Seno Medical Instruments, Inc. is a San Antonio, Texas-based medical imaging company formed to commercialize a new modality in cancer screening and diagnosis called opto-acoustic imaging. A strong, experienced management team and nationally ...
based inPleasanton, CALIFORNIA (USA)
Anchor Molecular is a life science diagnostics company specializing in the development of best-in-class quality controls, reference materials, and reagents for liquid biopsy assays. We focus on liquid biopsy cancer diagnostic test based on cell-free ...
based inNewark, CALIFORNIA (USA)
ACD - a Bio-Techne brand, shortens the path to personalized medicine and enables research, drug development and clinical applications by unlocking the power of RNA. ACD is a leader in the emerging field of molecular pathology, developing cell- and ...
based inSan Diego, CALIFORNIA (USA)
We are dedicated to one thing: improving outcomes for cancer patients. That’s why we focus on developing innovative diagnostic solutions that give patients and doctors the information they need—all from a simple blood test, known as a liquid biopsy. ...
based inWest Lafayette, INDIANA (USA)
Tymora Analytical Operations provides diagnostic development and exosome proteomics contract services and products for improved cancer research. Tymora’s primary goal is to enable the shift from tissue to liquid biopsy. Our new technologies allow ...
based inDoylestown, PENNSYLVANIA (USA)
Incorporated in PA in 2011, our MISSION is to translate our circulating cell-free DNA (cfDNA) in urine technology into improved cancer screening and management by liquid biopsy towards our VISION of decreased global cancer mortality. Our proprietary ...
based inNew York, NEW YORK (USA)
We are a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We have the brightest people in the industry and believe that their diverse ...
based inBoca Raton, FLORIDA (USA)
Clarity Diagnostics, LLC is a manufacturer and market leader of rapid diagnostic tests, diagnostic equipment, and over-the-counter rapid diagnostic tests that are targeted toward the Continuum of Care, Alternate Care, Acute Care, Laboratory, and OTC ...
Clarity understands that early detection of colorectal cancer in patients can be critical for successful treatment. In order to make it easier for your facility to screen for colorectal cancer in-house, Clarity has developed a product that makes the ...
based inGeorgetown, TEXAS (USA)
Ezra is focused on early cancer detection through the use of full-body MRI scans. Given that early detection significantly increases survival rates, Ezra's annual Full Body Scans aim to identify cancer signs early, potentially preventing late-stage ...
Ezra offers advanced MRI-based full-body scans aimed at early cancer detection. The service employs 3 Tesla (3T) MRI technology, known for its higher-resolution imaging and superior signal-to-noise ratio, alongside 1.5 Tesla (1.5T) MRI for broader ...
based inRichmond, BRITISH COLUMBIA (CANADA)
BioMark is an oncology-focused company with advanced near-to- market liquid biopsy diagnostic technologies. Our technology improves patient comfort, outcomes and early cancer detection. Biomark owns various intellectual properties, developed for the ...
BioMark’s initial liquid biopsy assay detects SSAT1 using an FDA approved drug. SSAT1 is an enzyme with elevated levels in numerous cancers. The assay targets a well researched and understood metabolic pathway. BioMark of a few unique ...
based inSykesville, MARYLAND (USA)
OTraces, Inc. has built, and extensively filed patents protection on, an early tumor detection and cancer screening software technology. Technology uses well-known math- and physics-based A-I methods including those used in advanced satellite ...
The OTraces technology platform drives multiple business opportunities. The software is embedded into a laboratory information management system (LIMS) wherein all patient and instrument data is stored in secure U.S. based servers. This software is ...
based inHuntsville, ALABAMA (USA)
Kailos Genetics provides consumers access to affordable physician-ordered genetic tests. It is our mission to help people take control of their health and make more informed decisions. The Kailos test is an easily accessible genetic test catered to ...
Kailos Iota combines TargetRich, our foundational genetic enrichment technology, with next-generation sequencing and statistical machine learning that results in a highly specific cancer assay of multiple solid tumors at all stages. The Iota assay ...
based inBoston, MASSACHUSETTS (USA)
Sherlock Biosciences is dedicated to providing global access to the simplest and most accurate tests that empower individuals to control their own healthcare. Through its Engineering Biology platforms, the company is developing applications of ...
based inEatontown, NEW JERSEY (USA)
Immunostics offers a broad portfolio of performance-driven diagnostics solutions that provide more effective ways to assist in the diagnosis of a disease. Our products offer the right balance of science, technology and practicality across the ...
Greater sensitivity than traditional guaiac-based methods. Increased specificity to lower GI bleeding makes hema-screen SPECIFIC GOLD an ideal tool for colon cancer ...
based inFort Myers, FLORIDA (USA)
NeoGenomics is a premier cancer diagnostic, pharma services, and information services company serving oncologists, pathologists, pharmaceutical companies, and academic centers in their pursuit of providing better futures for people living with ...
Histology, tissue staining using the latest in automated staining platforms, and digital pathology services form the foundation of a strong anatomic pathology program. Anatomic Pathology at NeoGenomics offers in-house comprehensive diagnostic ...
based inTucson, ARIZONA (USA)
D3Sciences is dedicated to the development of tools for improved tissue sampling to expand cancer diagnosis, therapy specificity, and research. Creating tools to improve tissue sampling for rapid, precise, and cost effective delivery of care to ...
Detecting, Diagnosing and Treating Cancer: To detect, diagnose, and treat internal cancer requires a team of healthcare providers led generally by three specialist physicians: oncologists, radiologists, and pathologists. Upon examining a patient, ...
based inSan Diego, CALIFORNIA (USA)
CureMetrix is committed to the advancement of technology that will improve cancer survival rates worldwide. Our research is focused on leveraging artificial intelligence and deep learning to develop the next generation of medical image analysis ...
cmAngio An investigational AI-based triage software that helps doctors assess a patient’s risk of coronary heart disease ...
based inCleveland, OHIO (USA)
Cleveland Diagnostics, Inc. is a commercial-stage diagnostics company developing highly efficacious, lab-friendly, affordable diagnostics tests using proprietary technology to improve cancer diagnostics. The Company’s Solvent Interaction Analysis ...
IsoPSA Proceed to biopsy only when needed. IsoPSA is now included in NCCN® Prostate Cancer Early Detection Guidelines. IsoPSA can help reduce unnecessary prostate biopsies by up to 55%. Up to 75% of results from prostate biopsies performed in ...
based inAustin, TEXAS (USA)
Natera is a global leader in cell-free DNA (cfDNA) testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health and inform earlier, more ...
Signatera is a personalized, tumor-informed assay optimized to detect circulating tumor DNA (ctDNA) for molecular residual disease (MRD) assessment and recurrence monitoring for patients previously diagnosed with cancer, with broad utility for ...
